FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

63 letters match. Newest first.

  1. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  2. Beaute Bounty

    FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.

    High risk
  3. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  4. R3 Medical Companies

    FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

    High risk
  5. Genzyme Ireland Limited

    Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.

    High risk
  6. Blue Horizon International, LLC

    FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.

    High risk
  7. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  8. IsoTis OrthoBiologics, Inc.

    IsoTis OrthoBiologics in Irvine, CA failed to properly fix and assess possible particulate contamination in its Accell bone filler devices, FDA says.

    High risk
  9. Dynamic Stem Cell Therapy

    FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.

    High risk
  10. Microvascular Tissue, Inc.

    FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.

    High risk
  11. Celularity, Inc

    FDA warns Celularity that Interfyl is an unapproved new drug and unlicensed biological product marketed for orthopedic and wound uses.

    High risk
  12. BioXtek LLC

    FDA says BioXtek's amniotic membrane products are unapproved new drugs and unlicensed biological products.

    High risk
  13. Lux Therapeutics LLC dba Ponya Therapeutics LLC

    FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.

    High risk
  14. Allovate Therapeutics, LLC

    FDA warned Allovate that its Allerdent allergenic toothpaste is an unapproved drug and lacks a required biologic license.

    High risk
  15. New Life Medical Services, LLC

    FDA says New Life Medical Services sells unapproved umbilical-cord, amniotic-fluid, and exosome products as drugs.

    High risk
  16. Cellebration LLC

    FDA warns Cellebration LLC over unapproved cord-blood cellular products and refusal to provide requested records.

    High risk
  17. CSL Behring

    FDA says CSL Behring's HIZENTRA TV ad overstates protection and plays down risks, misbranding the immune globulin biologic.

    Medium
  18. NuVida Medical LLC

    FDA says NuVida Medical sells unapproved, unlicensed tissue products for non-homologous wound care uses.

    High risk
  19. Platinum Biologics LLC

    FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.

    High risk
  20. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  21. Supreme Rejuvenation, LLC

    FDA warned Supreme Rejuvenation that its exosome products are unapproved new drugs and unlicensed biological products.

    High risk
  22. Skye Biologics Holdings LLC

    FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.

    High risk
  23. MG Infusions

    FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.

    High risk
  24. BioStem Life Sciences

    FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.

    High risk
  25. Chara Biologics, Inc.

    FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.

    High risk
  26. Evolutionary Biologics Inc.

    FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.

    High risk
  27. INCELL Corporation LLC

    FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.

    High risk
  28. XO Biologix, LLC

    XO Biologix markets MaviX, an amniotic-fluid product, as an unapproved new drug and unlicensed biologic.

    High risk
  29. Frontier Biologics, LLC

    FDA warned Frontier Biologics of Waco, Texas, that its amniotic fluid and membrane products are unapproved drugs and unlicensed biologics.

    High risk
  30. Pinnacle Transplant Technologies, LLC

    FDA warns Pinnacle Transplant Technologies over unapproved injectable amniotic products and sterility CGMP failures.

    High risk
  31. Amnio Technology, LLC

    FDA warned Amnio Technology over unapproved injectable amniotic products and serious manufacturing deviations at its Phoenix facility.

    High risk
  32. Hemarus LLC

    Hemarus LLC failed blood-product manufacturing rules, including unapproved donor reinstatement and records signed when physician absent.

    High risk
  33. Mother Stem Institute, Corp.

    FDA warns Mother Stem Institute over unapproved fat-derived SVF 'stem cell' biologic marketed for serious diseases.

    High risk
  34. CARsgen Therapeutics Corporation

    FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.

    High risk
  35. Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.

    FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.

    High risk
  36. Massachusetts Institute of Technology MIT

    FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.

    Medium
  37. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  38. Akan Biosciences, Inc.

    FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.

    High risk
  39. Human Microbes

    FDA warned Human Microbes that selling fecal microbiota for transplantation as an unapproved drug and unlicensed biologic lacks required BLA or IND.

    High risk
  40. MiMedx Group, Inc.

    FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.

    High risk
  41. Kimera Labs, Inc.

    FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.

    High risk
  42. Abbott Laboratories

    FDA warns Abbott that Similac Probiotic Tri-Blend for preterm infants is an unapproved drug and adulterated supplement.

    High risk
  43. Infinant Health, Inc formerly Evolve Biosystems Inc.

    FDA says Infinant Health's Evivo with MCT Oil probiotic is an unapproved biologic drug and unsafe food additive for preterm infants.

    High risk
  44. Signature Biologics, LLC

    FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.

    High risk
  45. RenatiLabs Inc.

    RenatiLabs marketed WJMAX, a human umbilical cord-derived biologic, without a license and released a lot that failed sterility testing.

    High risk
  46. Stratus Biosystems, LLC dba CellGenuity Regenerative Science

    FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.

    High risk
  47. Row1 Inc. dba Regenative Labs

    FDA warned Regenative Labs that its umbilical cord products are unlicensed drugs, made under serious sterility and manufacturing failures.

    High risk
  48. Invitrx Therapeutics, Inc.

    Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.

    High risk
  49. Sovereign Pharmaceuticals, LLC

    FDA cited Sovereign Pharmaceuticals for manufacturing failures in bulk tablets, inadequate out-of-specification (OOS) investigations, quality-unit lapses, and an unapproved biological product.

    High risk
  50. BioLab Sciences, Inc.

    FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.

    High risk